[Close]
- This page was created by volunteers like you!
- Help us make it even better. To learn more about contributing to MEpedia, click here.
- Join the movement
- Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
- Congratulations!
- MEpedia has got over 30 million views as of August 2022!
Proton pump inhibitor
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
 | This article is a stub. |
Proton pump inhibitors or PPIs are a class of drugs that reduce levels of stomach acid.[1]
Proton pump inhibitors may be used to treat symptoms of Gastroesophageal Reflux (GERD).
Warning: long term use of PPIs is considered a risk factor for the development of SIBO[2][3] (small intestinal bacterial overgrowth), which has symptoms like fatigue and brain fog that are quite similar to conditions Chronic fatigue syndrome.
Theory[edit | edit source]
Evidence[edit | edit source]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
List of proton pump inhibitors[edit | edit source]
Proton pump inhibitors include:
- Dexlansoprazole e.g., Dexilant, Kapidex
- Esomeprazole e.g., Nexium
- Pantoprazole e.g., Protonix
- Rabeprazole e.g., Aciphex[1]
Systemic mastocytosis[edit | edit source]
Proton pump inhibitors for systematic mastocytosis (which is not the same as mast cell activation disorder) include:
- Lansoprazole e.g., Prevacid, which is used for
- Omeprazole e.g., Prilosec[1][4]
See also[edit | edit source]
Learn more[edit | edit source]
- Proton pump inhibitors - drugs.com
- drugbank.ca
References[edit | edit source]
- ↑ Jump up to: 1.0 1.1 1.2 "List of Proton Pump Inhibitors + Uses, Side Effects". Drugs.com. Retrieved February 16, 2021.
- ↑ LO, WAI–KIT; CHAN, Walter W. (2013). "Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis". CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (11): 483–490.
- ↑ Su, Tingting; Lai, Sanchuan; Lee, Allen; He, Xingkang; Chen, Shujie (January 2018). "Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth". Journal of Gastroenterology. 53 (1): 27–36. doi:10.1007/s00535-017-1371-9. ISSN 1435-5922. PMID 28770351.
- ↑ "Medications for Systemic Mastocytosis". Drugs.com. Retrieved February 18, 2021.
